These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 33672357)
21. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis. Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047 [No Abstract] [Full Text] [Related]
22. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647 [TBL] [Abstract][Full Text] [Related]
23. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Riquelme E; Behrens C; Lin HY; Simon G; Papadimitrakopoulou V; Izzo J; Moran C; Kalhor N; Lee JJ; Minna JD; Wistuba II Cancer Res; 2016 Feb; 76(3):675-85. PubMed ID: 26676756 [TBL] [Abstract][Full Text] [Related]
24. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133 [TBL] [Abstract][Full Text] [Related]
25. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261 [TBL] [Abstract][Full Text] [Related]
26. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
27. Comparison of real-life data from patients with NGS panel negative and Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577 [TBL] [Abstract][Full Text] [Related]
35. Loss of wild type KRAS in KRAS Liu Y; Gao GF; Minna JD; Williams NS; Westover KD Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697 [TBL] [Abstract][Full Text] [Related]
36. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997 [No Abstract] [Full Text] [Related]
37. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma. Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673 [TBL] [Abstract][Full Text] [Related]
38. Targeting PI3Kα overcomes resistance to KRas Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339 [TBL] [Abstract][Full Text] [Related]
39. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493 [TBL] [Abstract][Full Text] [Related]
40. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition. Meeusen B; Cortesi EE; Domènech Omella J; Sablina A; Ventura JJ; Janssens V Cancer Lett; 2021 Nov; 520():57-67. PubMed ID: 34216687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]